e
narr
review
articl
glossari
angiotensinconvert
enzym
acei
angiotensinconvert
enzym
inhibitor
aha
american
heart
associ
alt
alanin
aminotransferas
arb
angiotensin
receptor
blocker
ard
acut
respiratori
distress
syndrom
btki
bruton
tyrosin
kinas
inhibitor
car
chimer
antigen
receptor
cbc
complet
blood
count
cdc
center
diseas
control
prevent
cfr
case
fatal
rate
coronaviru
diseas
crcl
creatinin
clearanc
ct
comput
tomographi
equat
enhanc
qualiti
transpar
health
research
esa
elect
surgeri
acuiti
scale
gi
gastrointestin
hmef
heat
moistur
exchang
filter
hsct
hematopoiet
stem
cell
transplant
icu
intens
care
unit
interleukin
jaki
janu
kinas
inhibitor
lft
liver
function
test
merscov
middl
east
respiratori
syndrom
coronaviru
oper
room
pacu
postanesthesia
care
unit
papr
power
airpurifi
respir
ppe
person
protect
equip
rsv
human
respiratori
syncyti
viru
sar
sever
acut
respiratori
syndrom
sever
acut
respiratori
syndrom
coronaviru
til
tumorinfiltr
lymphocyt
vegf
vascular
endotheli
growth
factor
novel
coronaviru
diseas
covid
first
emerg
outbreak
provinc
hubei
china
decemb
caus
virion
formal
known
sever
acut
respiratori
syndrom
coronaviru
beta
coronaviru
like
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
sar
thought
origin
anim
host
eventu
spread
human
becam
global
pandem
matter
month
affect
countri
total
infect
death
worldwid
march
coronavirus
constitut
larg
famili
virus
known
infect
human
anim
bat
implic
vector
largest
varieti
coronavirus
human
coronavirus
subclassifi
alpha
beta
coronavirus
clinic
manifest
coronaviru
infect
typic
respiratori
enter
although
present
neurolog
manifest
time
public
articl
thought
incub
period
approxim
week
infect
individu
becom
symptomat
day
exposur
ill
sever
rang
mild
critic
fatal
approxim
case
asymptomat
mild
symptom
sever
ill
critic
ill
due
test
avail
limit
true
case
fatal
rate
cfr
difficult
determin
believ
rang
base
exist
data
differ
countri
patient
typic
present
fever
cough
short
breath
gastrointestin
musculoskelet
neurolog
symptom
sever
patient
present
pneumonia
acut
respiratori
distress
syndrom
ard
progress
multiorgan
failur
ultim
succumb
viral
syndrom
review
adher
applic
enhanc
qualiti
transpar
health
research
equat
guidelin
underli
health
condit
increas
suscept
sever
includ
hypertens
chronic
obstruct
pulmonari
diseas
diabet
mellitu
cardiovascular
diseas
immunocompromis
state
autoimmun
diseas
nonautoimmun
inflammatori
diseas
patient
take
immunosuppress
agent
transplant
organ
activ
cancer
also
increas
suscept
sever
pandem
evolv
incid
rate
cancer
patient
suggest
higher
rate
sever
critic
diseas
one
prospect
cohort
studi
cancer
patient
observ
patient
cancer
higher
risk
sever
event
compar
patient
without
cancer
patient
recent
underw
chemotherapi
surgeri
higher
risk
clinic
sever
event
compar
patient
howev
sever
limit
includ
small
sampl
size
differ
cancer
type
variabl
diseas
cours
divers
treatment
strategi
contribut
age
risk
chines
center
diseas
control
prevent
cdc
publish
largest
case
seri
date
mainland
china
report
cfr
among
patient
cancer
insuffici
data
current
cancer
patient
requir
examin
past
studi
coronaviru
diseas
immunocompromis
popul
extrapol
risk
suscept
andor
develop
sever
nevertheless
nationwid
analysi
china
observ
patient
cancer
higher
risk
sever
event
compar
patient
without
cancer
patient
underw
chemotherapi
surgeri
previou
month
higher
risk
sever
event
note
cancer
patient
higher
risk
patient
poorer
outcom
patient
without
cancer
immunocompromis
patient
remain
vulner
respiratori
viral
infect
viral
pneumonia
associ
mortal
rate
immunocompromis
patient
specif
convent
coronavirus
shown
associ
higher
rate
oxygen
requir
mortal
patient
hematolog
malign
hematopoiet
cell
transplant
one
studi
coronaviru
pneumonia
mortal
cancer
patient
compar
noncanc
patient
furthermor
patient
tend
frequent
prolong
viral
shed
immun
system
alter
sever
way
cancer
patient
put
increas
risk
infect
result
specif
cancer
therapi
extent
diseas
locat
primari
diseas
origin
lymphopenia
observ
patient
advanc
cancer
diseas
patient
local
diseas
lymphopenia
seen
varieti
cancer
type
pancreat
melanoma
sarcoma
hepatocellular
nonhodgkin
lymphoma
colon
cancer
sever
studi
patient
hematolog
malign
respiratori
viral
infect
lymphopenia
independ
predict
progress
pneumonia
laboratori
find
patient
includ
lymphopenia
hospit
patient
nonsurvivor
develop
sever
lymphopenia
time
platelet
also
play
import
immun
system
role
viricid
effect
virus
cancer
invad
displac
normal
bone
marrow
leukemia
lymphoma
lead
thrombocytopenia
associ
immunocompromis
state
effect
immun
respons
viral
infect
depend
activ
cell
help
clear
infect
recent
studi
patient
nonintens
care
unit
icu
case
decreas
total
cell
wherea
icu
patient
decreas
total
cell
therapi
contribut
immunocompromis
state
chemotherapi
use
corticosteroid
immunosuppress
therapi
risk
factor
sever
respiratori
viral
infect
chemotherapi
damag
bone
marrow
cell
lead
thrombocytopenia
neutropenia
render
patient
suscept
infect
patient
greater
risk
nadir
period
neutrophil
number
lowest
nadir
occur
day
complet
dose
chemotherapi
sometim
last
week
chemotherapeut
agent
depress
immun
system
cytotox
agent
caus
bone
marrow
suppress
temozolomid
cyclophosphamid
paclitaxel
methotrex
alemtuzumab
increas
infect
risk
cancer
patient
chemotherapi
drug
cyclophosphamid
cisplatin
methotrex
fludarabin
tax
among
potent
agent
result
lymphopenia
sinc
limit
data
avail
estim
mortal
risk
patient
undergo
chemotherapi
becom
infect
articl
use
model
extrapol
risk
found
cancer
patient
mortal
risk
infect
older
patient
solid
tumor
greater
risk
harm
like
outweigh
benefit
chemotherapi
patient
recommend
made
postpon
adjuv
chemotherapi
stabl
cancer
activ
pandem
area
base
limit
data
decis
initi
continu
cytotox
chemotherapi
need
consid
individu
care
radiat
treatment
affect
immun
system
highdos
bodi
irradi
signific
risk
factor
progress
lower
respiratori
tract
infect
respiratori
syncyti
viru
rsv
hematopoiet
cell
transplant
patient
lymphocyt
affect
extern
beam
radiat
result
radiationinduc
lymphopenia
lymphocyt
expos
irradi
field
direct
toxic
effect
phenomenon
report
occur
patient
undergo
convent
extern
beam
radiat
therapi
risk
mitig
use
proton
beam
therapi
stereotact
bodi
radiat
hypofraction
schedul
clear
guidelin
continu
initi
radiat
therapi
pandem
case
review
individu
level
riskbenefit
analysi
immunotherapi
treat
certain
cancer
type
includ
immun
checkpoint
inhibitor
tcell
transfer
therapi
vaccin
immunemodul
agent
welldefin
guidelin
continu
initi
immunotherapi
pandem
howev
side
effect
therapi
may
serv
guid
decis
make
basi
side
effect
due
hyperactiv
tcell
respons
reactiv
direct
normal
tissu
immun
checkpoint
inhibitor
rare
side
effect
thrombocytopenia
pneumon
tcell
transfer
therapi
consist
tumorinfiltr
lymphocyt
til
chimer
antigen
receptor
car
tcell
therapi
side
effect
til
includ
prolong
lymphopenia
car
tcell
therapi
lead
cytokin
releas
syndrom
cancer
vaccin
associ
minim
toxic
final
certain
immunemodul
agent
caus
thrombocytopenia
anemia
leukopenia
vascular
permeabl
lead
pleural
effus
pulmonari
edema
interestingli
immunemodul
agent
diminish
inflamm
infect
shown
therapeut
promis
mice
model
infect
variou
influenza
strain
bone
marrow
transplant
sever
viral
respiratori
diseas
highest
morbid
mortal
observ
patient
hematopoiet
stem
cell
transplant
hsct
treatment
essenti
elimin
host
immun
system
replac
donor
patient
vulner
infect
first
month
transplant
recoveri
baselin
extend
year
case
cancer
patient
infecti
risk
specif
cancer
patient
particularli
high
risk
infect
due
cancer
type
treatment
patient
blood
malign
involv
immun
system
cell
lymphoma
aplast
anemia
myeloma
leukemia
vulner
infect
virtu
cancer
janu
kinas
inhibitor
jaki
bruton
tyrosin
kinas
inhibitor
btki
use
treatment
certain
cancer
includ
leukemia
lymphoma
also
caus
immunosuppress
inhibit
cytokin
growth
factor
signal
pathway
inhibit
bcell
matur
respect
nosocomi
infect
common
cancer
patient
increas
risk
viral
bacteri
fungal
pathogen
patient
hospit
suscept
variou
respiratori
infect
human
rsv
influenza
b
virus
parainfluenza
viru
human
metapneumoviru
patient
undergon
hsct
acquir
parainfluenza
virus
lower
respiratori
tract
involv
greater
likelihood
respiratori
failur
death
addit
hsct
patient
communityacquir
pulmonari
viral
infect
sever
lower
respiratori
tract
involv
late
airway
outflow
obstruct
multipl
fungal
bacteri
coinfect
postsurg
infect
common
often
sever
complic
cancer
patient
depend
type
locat
tumor
size
lymph
node
involv
organ
involv
subsequ
infecti
complic
rang
minor
moder
sever
bevacizumab
angiogenesi
inhibitor
work
block
vascular
endotheli
growth
factor
vegf
caus
signific
delay
wound
heal
oblig
time
surgic
resect
variou
cancer
type
surgeri
tumor
locat
also
signific
effect
postop
infect
oral
maxillofaci
tumor
resect
complex
reconstruct
radic
neck
dissect
prolong
length
surgeri
hour
need
blood
transfus
associ
infect
rate
younger
cancer
survivor
often
robust
reconstitut
immun
system
compar
older
survivor
howev
survivor
age
higher
rate
infecti
complic
compar
noncanc
counterpart
cancer
survivor
like
hospit
respiratori
infect
increas
particul
matter
pollut
least
time
like
develop
sepsi
increas
infectiousrel
mortal
rate
cancer
patient
infect
may
increas
morbid
mortal
noncanc
patient
infect
liang
et
al
analysi
case
includ
patient
cancer
histori
patient
unknown
cancer
treatment
patient
recent
cancer
treatment
cancer
patient
older
histori
smoke
dyspnea
advanc
comput
tomographi
ct
scan
find
without
cancer
report
patient
higher
risk
sever
event
icu
admiss
mechan
ventil
death
patient
recent
cancer
treatment
experienc
sever
event
patient
cancer
exhibit
faster
clinic
deterior
vs
day
small
studi
sampl
size
age
bia
year
cancer
group
versu
year
noncanc
group
higher
rate
smoke
cancer
cohort
limit
extern
valid
generaliz
find
recent
studi
william
et
al
creat
model
estim
mortal
risk
agematch
cancer
patient
infect
articl
base
data
chines
cdc
italian
public
health
author
cohort
diamond
princess
cruis
ship
william
et
al
demonstr
strong
effect
age
mortal
year
increas
cfr
due
cancer
chemotherapi
conclud
cancer
patient
mortal
compar
cancerfre
patient
increas
mortal
greater
purport
aggreg
benefit
solid
tumor
chemotherapi
malign
sever
immun
deficit
like
greatest
risk
includ
lymphoma
leukemia
multipl
myeloma
sever
viral
respiratori
diseas
highest
morbid
mortal
found
patient
myelosuppress
hematopoiet
cell
transplant
risk
factor
lower
respiratori
tract
diseas
includ
age
year
graft
versu
host
diseas
corticosteroid
use
neutropenia
lymphopenia
hypoalbuminemia
effect
immun
respons
viral
infect
depend
activ
cell
assist
clear
infect
approxim
million
case
tobaccoassoci
cancer
report
unit
state
lung
cancer
account
onethird
case
major
also
diagnos
chronic
obstruct
pulmonari
diseas
one
prospect
cohort
studi
determin
frequent
type
cancer
among
patient
lung
cancer
case
recent
data
demonstr
significantli
higher
angiotensinconvert
enzym
gene
express
former
smoker
lung
compar
nonsmok
lung
bind
host
cell
receptor
critic
step
viral
cell
entri
enzym
import
regul
immun
respons
particularli
acut
lung
injuri
murin
studi
observ
overexpress
lead
protect
effect
acut
lung
injuri
possibl
mechan
includ
prolifer
receptor
viru
bind
lead
greater
risk
perhap
increas
gene
express
confer
protect
immunolog
mechan
investig
need
determin
whether
smoker
greater
risk
acut
lung
injuri
viral
infect
periop
manag
patient
suspect
confirm
focus
sever
aspect
includ
region
institutionspecif
factor
patient
commun
employe
safeti
conserv
resourc
staff
hospit
bed
equip
suppli
march
organ
american
colleg
surgeon
ambulatori
surgeri
center
associ
provid
guidanc
manag
nonemerg
surgic
procedur
set
procedur
safe
postpon
without
signific
risk
patient
delay
pandem
cancer
patient
pose
uniqu
manag
dilemma
viral
pandem
like
cancer
lifethreaten
diseas
process
cancer
vari
natur
histori
prognosi
mortal
rate
patient
regardless
cancer
type
struggl
feel
anxieti
fear
allevi
relief
hope
come
medic
surgic
treatment
henc
accord
tool
like
elect
surgeri
acuiti
scale
esa
use
triag
nonemerg
oper
cancer
surgeri
consid
high
acuiti
proceed
plan
assum
resourc
avail
certain
procedur
surgeri
eg
otolaryngolog
dental
pulmonari
gastroenterolog
high
risk
aerosol
viru
regardless
cancer
statu
mani
profession
societi
releas
statement
delay
restrict
reschedul
nonurg
procedur
consider
alway
made
avoid
highrisk
aerosol
procedur
case
must
proceed
due
lifethreaten
circumst
provid
involv
care
attir
appropri
person
protect
equip
ppe
mask
eye
protect
waterresist
gown
glove
furthermor
procedur
perform
neg
pressur
room
avail
care
must
taken
preoper
close
screen
patient
influenzalik
symptom
arriv
hospit
may
done
telephon
call
hospit
arriv
addit
screen
hospit
admiss
number
caregiv
direct
contact
patient
xxx
xxx
volum
xxx
number
xxx
wwwanesthesiaanalgesiaorg
limit
necessari
throughout
periop
period
patient
suspect
confirm
requir
emerg
surgeri
avoid
preoper
hold
area
instead
transport
directli
design
oper
room
prefer
mobil
isol
unit
sign
post
entri
point
attempt
made
minim
health
care
staff
exposur
ensur
requir
staff
remain
ppe
essenti
health
care
provid
throughout
periop
period
ensur
airbornedropletcontact
isol
precaut
achiev
full
ppe
airway
manipul
includ
fittest
dispos
respir
power
airpurifi
respir
papr
goggl
face
shield
waterresist
gown
doubl
glove
protect
footwear
protocol
don
dof
ppe
must
strictli
adher
experienc
anesthesia
provid
perform
intub
especi
patient
sever
ill
video
laryngoscopi
consid
adequ
paralysi
ensur
intub
avoid
aerosol
gener
buck
cough
postop
phase
patient
suspect
confirm
transfer
postanesthesia
care
unit
pacu
patient
recov
transfer
directli
airborn
isol
infect
room
minim
contamin
heat
moistur
exchang
filter
hmef
remov
airborn
particl
greater
appli
endotrach
tube
transfer
patient
left
much
time
possibl
allow
subsequ
patient
care
optim
decontamin
visitor
polici
may
fluid
restrict
rang
limit
number
visitor
per
patient
strict
novisitor
polici
determin
feder
state
mandat
except
may
consid
special
situat
endoflif
pediatr
care
date
treatment
patient
center
support
measur
sever
treatment
modal
current
avail
patient
exist
therapi
still
investig
certain
drug
proven
help
overal
treatment
determin
infect
sever
patient
comorbid
patient
mild
infect
selflimit
cours
recov
unev
home
manag
focu
patient
isol
prevent
spread
other
patient
moder
symptom
pneumonia
may
requir
hydroxychloroquin
azithromycin
addit
support
care
tabl
anecdot
hydroxychloroquin
azithromycin
shown
potenti
prophylaxi
treatment
patient
note
combin
drug
appear
reinforc
benefici
effect
significantli
decreas
viral
load
therebi
reduc
length
infect
bronchodil
need
moder
infect
meter
dose
inhal
recommend
instead
nebul
treatment
limit
viral
spread
remdesivir
lopinavirritonavir
current
recommend
patient
sever
symptom
includ
ard
requir
mechan
ventil
tabl
patient
sever
symptom
cytokin
releas
syndrom
ard
acut
lung
injuri
high
level
inflammatori
marker
start
tocilizumab
refractori
sever
infect
worsen
symptom
interferon
convalesc
plasma
consid
tabl
previous
mention
cancer
patient
immunocompromis
state
like
present
sever
diseas
state
like
pneumonia
ard
may
warrant
intub
mechan
ventil
consider
aforement
drug
therapi
special
caution
must
taken
immunosuppress
cancer
patient
prescrib
tocilizumab
interferon
recommend
made
individu
basi
us
cdc
recommend
avoid
steroid
treatment
american
heart
associ
aha
recommend
continu
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
patient
alreadi
prescrib
medic
periop
import
continu
prescrib
treatment
medic
understand
associ
consider
review
cancer
patient
base
latest
inform
knowledg
avail
medic
commun
time
pandem
continu
evolv
unfold
like
health
care
commun
face
addit
yet
unknown
challeng
imper
stay
abreast
develop
protect
frontlin
health
care
provid
provid
vulner
patient
care
need
best
chanc
surviv
return
optim
health
e
